Illumina (ILMN) Stock Price, News & Analysis

20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 2 sell ratings, 10 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ILMN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View ILMN analyst ratings or view top-rated stocks.

20 analysts have issued 12-month price targets for Illumina's shares. Their ILMN share price targets range from $100.00 to $253.00. On average, they predict the company's share price to reach $164.65 in the next twelve months. This suggests a possible upside of 49.0% from the stock's current price.
View analysts price targets for ILMN or view top-rated stocks among Wall Street analysts.

Illumina's stock was trading at $139.24 at the beginning of the year. Since then, ILMN stock has decreased by 20.6% and is now trading at $110.53.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024.
View our ILMN earnings forecast.

Illumina, Inc. (NASDAQ:ILMN) posted its quarterly earnings results on Thursday, May, 2nd. The life sciences company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.05. The life sciences company had revenue of $1.08 billion for the quarter, compared to analysts' expectations of $1.05 billion. Illumina had a positive trailing twelve-month return on equity of 2.31% and a negative net margin of 28.71%. The company's revenue was down 1.0% on a year-over-year basis. During the same period last year, the company earned $0.08 EPS.
Read the conference call transcript.

ETFs with the largest weight of Illumina (NASDAQ:ILMN) stock in their portfolio include VanEck Biotech ETF (BBH), Global X Telemedicine & Digital Health ETF (EDOC), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Global X Genomics & Biotechnology ETF (GNOM), First Trust NYSE Arca Biotechnology Index Fund (FBT), Tema Oncology ETF (CANC), Principal Healthcare Innovators ETF (BTEC) and iShares Biotechnology ETF (IBB).

Illumina issued an update on its FY 2024 earnings guidance on Tuesday, April, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $4.4 billion-$4.4 billion, compared to the consensus revenue estimate of $4.5 billion.

496 employees have rated Illumina Chief Executive Officer Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among the company's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Walt Disney (DIS), PayPal (PYPL), Salesforce (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

Illumina's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (11.45%), Baillie Gifford & Co. (3.60%), WCM Investment Management LLC (2.12%), Bank of New York Mellon Corp (1.78%), Findlay Park Partners LLP (0.46%) and Chevy Chase Trust Holdings LLC (0.33%). Insiders that own company stock include Aimee L Hoyt, Alexander Aravanis, Charles Dadswell, Jacob Thaysen, Jay T Flatley, Phillip G Febbo, Susan H Tousi and Susan H Tousi.
View institutional ownership trends.

Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.